Adial Pharmaceuticals Completes Pharmacokinetic Study for AD04, Paving the Way for Phase 3 Trials in Alcohol Use Disorder

Adial Pharmaceuticals has successfully completed a pharmacokinetic (PK) study of its drug candidate AD04 for Alcohol Use Disorder (AUD). This study, which met FDA requirements, provides crucial data for optimizing the design of upcoming Phase 3 clinical trials and potentially securing approval through a 505(b)(2) pathway. The results demonstrated that AD04 delivers lower ondansetron exposure than standard ondansetron tablets due to its lower dose, but exposure increases proportionally with dose and can be taken with or without food.

Sanctions on Chinese Banks Threaten ‘China Proxy’ Trade

Sanctions imposed on Chinese banks could have ripple effects on the ‘China proxy’ trade, which involves investing in currencies and assets that are expected to benefit from China’s economic growth. One such currency is the Australian dollar (AUD), which has been seen as a proxy for the Chinese yuan. However, if Chinese banks are sanctioned, it could reduce demand for the yuan and, by extension, the AUD.

Scroll to Top